Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Amgen Recalled Nearly 1 Million Bottles of Corlanor for Heart Failure: Check if You Have an Affected Lot

Amgen recalled 934,577+ bottles of Corlanor (ivabradine) in June 2026 over foreign substance on tablets. Check your lot number — and do not stop the drug without your doctor.

Medical Daily

Amgen Earnings Preview: What to Expect

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Colorado was the first state to cap a drug’s price – then a federal court stepped in

Colorado is one of a handful of states with a review board for drug prices and one of only four with a board empowered to set upper limits on what state agencies, insurers and other purchasers may pay or be reimbursed for certain high-cost drugs dispensed to patients in the…

The Conversation

Your Insurance Plan May Be Pocketing the Drug Coupon Card Meant to Help You Pay for Medication

Nearly 40% of ACA marketplace plans use copay accumulators to pocket drug coupon cards meant for patients. Here is how to check your plan and protect yourself.

Medical Daily

The Clinical Trial That Supported Tavneos for ANCA Vasculitis Was Just Retracted

NEJM retracted the Tavneos ADVOCATE trial on June 29, 2026, after FDA found altered patient data. Patients should not stop Tavneos without a doctor — here's what's known.

Medical Daily

Nearly 1 Million Bottles of a Heart Failure Drug Were Just Recalled — Check Your Medicine Cabinet

Amgen recalled ~934,577 bottles of Corlanor (ivabradine) for heart failure after foreign substance was found. The FDA classified it Class II. Check your lot number now.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Getting past the pilot: Why so many AI test projects have trouble scaling

Business leaders from Salesforce, Amgen, and Thomson Reuters took a hard look at AI pilot projects to understand why some thrive and some flail.

Fortune

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

MarketBeat

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

MarketBeat

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat

The CEO who loves AI autodidacts — and desperately needs his experts

Bob Bradway bet on AI before almost anyone else in biotech. Now Amgen is reaping the rewards — and wrestling with what it means for its scientists.

Fortune

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stocks Grind Higher on Good Fundamentals: Stock Market Today

The stock market is a forward-looking mechanism, and what it sees at the bottom line carries greater weight right now than geopolitical uncertainty.

Barchart

Why Wall Street Thinks This Dividend Stock Could Jump 30%

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Kiplinger

S&P 500 Hits New High on Apple Earnings: Stock Market Today

Apple rounded out a big week of mega-cap earnings on a high note, sending two of the three main equity indexes to new highs on Friday.

Barchart

What to Expect From Amgen's Next Quarterly Earnings Report

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Dow Leads in Mixed Session on Amgen Earnings: Stock Market Today

The rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.

Barchart

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart

Amgen Stock: Is Wall Street Bullish or Bearish?

Are Wall Street analysts bullish or bearish on Amgen’s stock prior to its Q4 earnings release?

Kiplinger

Dow Hits New High Then Falls 466 Points: Stock Market Today

The Nasdaq Composite, with a little help from tech's friends, rises to within 300 points of its own new all-time high.

GOBankingRates

6 Dividend Stocks Retirees Are Quietly Buying for Steady Income

For retirees, dividend stocks can offer the best of both worlds. The most obvious is a steady income stream, one that often increases over time. The other is the potential for capital appreciation,...

MarketBeat

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

Benzinga

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.